Meeting
2014 ASCO Annual Meeting
Phase I trial of cetuximab, intensity modulated radiotherapy (IMRT), and the anti-CTLA-4 monoclonal antibody (mAb) ipilimumab in previously untreated, locally advanced head and neck squamous cell carcinoma (PULA HNSCC).
Authors
Julie E. Bauman
University of Pittsburgh Cancer Institute, Pittsburgh, PA
Julie E. Bauman , William E. Gooding , David Andrew Clump , Seungwon Kim , Brian J Karlovits , Dwight Earl Heron , Umamaheswar Duvvuri , James Ohr , Karen Holeva , Robert L. Ferris
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Head and Neck Cancer
Track
Head and Neck Cancer
Sub Track
Head and Neck Cancer
Clinical Trial Registration Number
NCT01935921
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr TPS6104)
DOI
10.1200/jco.2014.32.15_suppl.tps6104
Abstract #
TPS6104
Poster Bd #
135B
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Phase I study of functionalized hafnium oxide nanoparticles (NBTXR3) activated by radiotherapy in cisplatin-ineligible locally advanced HNSCC patients.
First Author: Christophe Le Tourneau
Poster
2020 ASCO Virtual Scientific Program
Phase I trial of hafnium oxide nanoparticles activated by radiotherapy in cisplatin-ineligible locally advanced HNSCC patients.
First Author: Christophe Le Tourneau
Poster
2017 ASCO Annual Meeting
Phase Ib study of cetuximab + BYL719 + IMRT in stage III-IVB head and neck squamous cell carcinoma (HNSCC).
First Author: Lara Dunn
Poster
2017 ASCO Annual Meeting
Phase I study of the anti-HGF monoclonal antibody (mAb), ficlatuzumab, and cetuximab in cetuximab-resistant, recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).
First Author: Julie E. Bauman